A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects

Trial Profile

A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 25 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Feb 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 according to ClinicalTrials.gov record.
    • 15 Oct 2013 Planned number of patients changed from 50 to 70 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top